News & SEC Filings

View the latest news and SEC filings

News

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…

SEC Filings

Date Form Filing Group

February 29, 2024

Report of unscheduled material events or corporate event

8-K

Current Reports

February 14, 2024

An amendment to the SC 13G filing

SC 13G/A

Other

February 14, 2024

An amendment to the SC 13G filing

SC 13G/A

Other

February 9, 2024

A statement of beneficial ownership of common stock by certain persons

SC 13G

Other

February 8, 2024

A statement of beneficial ownership of common stock by certain persons

SC 13G

Other

February 5, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

February 5, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

February 5, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

February 5, 2024

Statement of changes in beneficial ownership of securities

4

3,4,5

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.